<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0"><channel><title>CNS</title><link>https://nrouizem.github.io/test/cns_feed.xml</link><description>Daily curated &amp; summarized biopharma news.</description><atom:link href="https://nrouizem.github.io/test/cns_feed.xml" rel="self"/><docs>http://www.rssboard.org/rss-specification</docs><generator>python-feedgen</generator><language>en</language><lastBuildDate>Thu, 13 Mar 2025 02:01:35 +0000</lastBuildDate><item><title>How Capsida’s unconventional funding strategy and capsid technology promise to reshape CNS treatments</title><link>https://www.drugdiscoverytrends.com/how-capsidas-unconventional-funding-strategy-and-capsid-technology-promise-to-reshape-cns-treatments/</link><description>Capsida Biotherapeutics has secured a $40 million license payment from AbbVie as it exercises its option on their first neurodegenerative disease program. The startup has successfully leveraged partnerships with Big Pharma to fund its innovative approaches in gene therapy for central nervous system treatments.</description><pubDate>Sat, 01 Feb 2025 21:05:12 +0000</pubDate></item><item><title>A B-vitamin rescues Parkinson-like damage in flies, pointing to new neuroprotective strategy</title><link>https://www.drugdiscoverytrends.com/a-b-vitamin-rescues-parkinson-like-damage-in-flies-pointing-to-new-neuroprotective-strategy/</link><description>A recent study published in Science Signaling highlights the potential of biotin (vitamin B7) as a neuroprotective agent against manganese-induced neurotoxicity associated with Parkinson’s disease. The research, conducted using fruit fly models and human dopaminergic neurons, found that biotin supplementation can reverse neurological damage caused by excessive manganese exposure.</description><pubDate>Thu, 27 Feb 2025 02:10:50 +0000</pubDate></item><item><title>Vertex’s new pain drug gets first coverage nod from major insurer</title><link>https://www.biopharmadive.com/news/vertex-journavx-optum-united-health-coverage-tier-3/741850/</link><description>Optum Rx, a UnitedHealth Group subsidiary, has temporarily added Journavx to select commercial formularies as part of an interim decision pending a full review. The move signals a potential partnership opportunity while the pharmacy benefit manager evaluates the drug’s long-term inclusion.</description><pubDate>Thu, 06 Mar 2025 22:59:00 +0000</pubDate></item><item><title>J&amp;J Axes Late-Stage Depression Trial After Underwhelming Efficacy</title><link>https://www.biospace.com/drug-development/j-j-axes-late-stage-depression-trial-after-underwhelming-efficacy</link><description>Despite aticaprant's Phase III setback, analysts say J&amp;J's neuroscience strategy remains intact, bolstered by its recent $14.6 billion acquisition of Intra-Cellular Therapeutics. The company’s confidence is further reinforced by the continued success of Spravato, its treatment for resistant depression, positioning it to maintain momentum in the sector.</description><pubDate>Fri, 07 Mar 2025 13:46:12 +0000</pubDate></item><item><title>J&amp;J scraps depression testing for potential blockbuster drug</title><link>https://www.biopharmadive.com/news/johnson-depression-studies-discontinue-aticaprant-neumora/741922/</link><description>A recent decision has dealt a "big blow" to a promising class of brain therapies, including Johnson &amp; Johnson’s experimental drug aticaprant and Neumora Therapeutics’ candidate, casting uncertainty over their development. While the article highlights setbacks for these specific treatments, it does not mention any new business deals, partnerships, or acquisitions related to the companies involved.</description><pubDate>Fri, 07 Mar 2025 17:08:00 +0000</pubDate></item><item><title>Virtual physical therapy startup Hinge Health files to go public</title><link>https://endpts.com/virtual-physical-therapy-startup-hinge-health-files-to-go-public/</link><description>Hinge Health, a virtual physical therapy startup focused on treating musculoskeletal issues and chronic pain through remote software, has filed for an IPO, ending a lull in digital health public offerings. The company aims to list on a stock exchange, marking a potential resurgence in investor confidence for the telehealth sector.</description><pubDate>Tue, 11 Mar 2025 04:00:11 +0000</pubDate></item><item><title>Lundbeck’s amlenetug gains orphan drug status in Japan for MSA</title><link>https://www.pharmaceutical-technology.com/news/lundbeck-amlenetug-japan-msa/</link><description>Lundbeck has received Orphan Drug Designation (ODD) from Japan's Ministry of Health, Labor and Welfare for its treatment amlenetug aimed at combating multiple system atrophy (MSA). This recognition paves the way for potential accelerated development and commercialization in the Japanese market.</description><pubDate>Tue, 11 Mar 2025 13:47:36 +0000</pubDate></item></channel></rss>